[Improved survival in advanced or metastatic prostate cancer with initial androgen deprivation and concomitant abiraterone]
Strahlenther Onkol
.
2018 Mar;194(3):266-268.
doi: 10.1007/s00066-017-1252-4.
[Article in German]
Authors
Cedric Oliver Carl
1
,
Rudolf Schwarz
2
,
Cordula Petersen
2
Affiliations
1
Klinik für Strahlentherapie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. ce.carl@uke.de.
2
Klinik für Strahlentherapie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
PMID:
29302703
DOI:
10.1007/s00066-017-1252-4
No abstract available
Publication types
Comment
MeSH terms
Androgen Antagonists
Androstenes*
Humans
Male
Prostatic Neoplasms*
Substances
Androgen Antagonists
Androstenes
abiraterone